Subsequently, the down-regulation of MYCN results in inhibition of the expression of its transcriptional targets including the tumor suppressor p53, indicating that differential functions among the p53 family may be causally related to the conflicting cellular responses to ATRA treatment such as promoting neuronal differentiation and/or apoptosis in neuroblastomas. The gene discussed is TP53; the disease is neuroblastoma.